2011年经阴道网片严重并发症通知发布后盆腔器官脱垂手术中同期压力性尿失禁手术的应用
本研究回顾性分析2009至2015年775例盆腔器官脱垂手术患者,评估2011年FDA关于经阴道网片公共卫生通知前后,术前压力性尿失禁评估、同期抗尿失禁手术及术后抗尿失禁手术的趋势。结果发现通知后同期抗尿失禁手术比例从54.8%降至38.0%(p=0.002),而术前主观及客观压力性尿失禁发生率保持稳定,术后1年内抗尿失禁手术发生率仍低。作者认为需进一步分析FDA通知对治疗模式的影响。
要点
- 2011年FDA通知后,盆腔器官脱垂修复时同期抗尿失禁手术比例由54.8%降至38.0%(p=0.002)。
- 术前主观及客观压力性尿失禁发生率在通知前后保持稳定。
- 术后1年内抗尿失禁手术发生率仍低。
核心结论
- 2011年FDA通知后,尽管术前主观或可证实的压力性尿失禁未见显著下降,盆腔器官脱垂修复时同期抗尿失禁手术发生率下降。
- 作者认为需进一步分析以评估FDA通知对盆腔器官脱垂合并压力性尿失禁女性治疗模式的影响。
研究设计与样本
- 回顾性审查2009至2015年在本机构接受盆腔器官脱垂手术患者的记录,共775例女性。
- 术前评估包括主观压力性尿失禁评估和/或体格检查时脱垂复位后漏尿评估、尿动力学或子宫托试验。
- 比较2011年FDA通知前后同期及术后抗尿失禁手术的百分比。
主要发现
- 盆腔器官脱垂修复时抗尿失禁手术比例在FDA通知后从54.8%降至38.0%(p=0.002)。
- 术前客观压力性尿失禁在体格检查、尿动力学和子宫托试验中的发生率保持恒定。
- 索引手术后1年内术后抗尿失禁手术发生率仍低。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: There is controversy regarding the performance of concomitant anti-incontinence procedures at the time of pelvic organ prolapse repair. Data support improvement in stress urinary incontinence with a concomitant sling but increased adverse events. We assessed trends in preoperative stress urinary incontinence evaluation, concomitant anti-incontinence procedure at pelvic organ prolapse surgery and postoperative anti-incontinence procedures at our institution before and after the 2011 FDA (U.S. Food and Drug Administration) Public Health Notification pertaining to vaginal mesh. MATERIALS AND METHODS: We retrospectively reviewed the records of patients who underwent pelvic organ prolapse surgery from 2009 to 2015. Preoperative workup included assessment of subjective stress urinary incontinence and/or evaluation for leakage with reduction of pelvic organ prolapse on physical examination, urodynamics or a pessary trial. The percentages of concomitant and postoperative anti-incontinence procedures were compared before and after the 2011 FDA notification. RESULTS: A total of 775 women underwent pelvic organ prolapse repair. The percentage of anti-incontinence procedures at pelvic organ prolapse repair decreased from 54.8% to 38.0% after the FDA notification (p = 0.002) while the incidence of preoperative objective stress urinary incontinence on examination, urodynamics and pessary trials remained constant. The incidence of postoperative anti-incontinence procedures within 1 year of the index surgery remained low. CONCLUSIONS: We found a decrease in the incidence of concomitant anti-incontinence procedures at the time of pelvic organ prolapse repair following the 2011 FDA notification despite no significant decline in subjective stress urinary incontinence or demonstrable stress urinary incontinence on preoperative evaluation. Further analysis is warranted to assess the impact of the FDA notification on treatment patterns in women with pelvic organ prolapse and stress urinary incontinence.
引用
- Drain A, Khan A, Ohmann EL, et al. Use of Concomitant Stress Incontinence Surgery at Time of Pelvic Organ Prolapse Surgery Since Release of the 2011 Notification on Serious Complications Associated with Transvaginal Mesh. J Urol. 2016. PMID: 27866958. doi:10.1016/j.juro.2016.11.087
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。